Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.57 |
| ▸ | BCL2 | P10415 | 1/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | CTSS | P25774 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 1/20 | 0.48 |
| ▸ | MMP3 | P08254 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.46 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.43 |
| ▸ | KIF11 | P52732 | 1/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.43 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13266542 | 0.87 | GABRG2 (0.49) | CYP2A6BCL2CTSSCTSKNISCH | |
| SCHEMBL5912019 | 0.82 | TSHR (0.69) | CTSSCTSKMMP3TSHRHSD17B10 | |
| SCHEMBL6252969 | 0.82 | TSHR (0.69) | CTSSCTSKMMP3TSHRHSD17B10 | |
| SCHEMBL1998639 | 0.82 | MMP3 (0.47) | MMP3TSHRHSD17B10HRH3CYP11B2 | |
| SCHEMBL16675765 | 0.82 | PRKCI (0.56) | MMP3HRH3CYP11B2FGFR1LOXL2 | |
| SCHEMBL8982347 | 0.82 | CYP2A6 (0.57) | CYP2A6CTSSCTSK | |
| SCHEMBL10244532 | 0.82 | CYP2A6 (0.57) | CYP2A6CTSSCTSK | |
| SCHEMBL3721300 | 0.82 | LOXL2 (0.62) | MMP3HRH3CYP11B2FGFR1LOXL2 | |
| SCHEMBL24272446 | 0.81 | CTSS (0.50) | CYP2A6PTGS2CTSSCTSKMMP3 | |
| SCHEMBL23621741 | 0.81 | KIF11 (0.47) | CYP2A6MMP3TSHRHSD17B10HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270381-A1 | Non-steroidal progesterone receptor modulators | BAYER SCHERING PHARMA AG (DE) | 2009-10-29 | — | — | US | disclosed |
| WO-2009077186-A1 | NONSTEROIDAL PROGESTERONE RECEPTOR MODULATORS | BAYER SCHERING PHARMA AKTIENGESLLSCHAFT (DE) | 2009-06-25 | — | — | WO | disclosed |
| EP-2070909-A1 | Non-steroidal progesterone receptor modulators | Bayer Schering Pharma AG (DE) | 2009-06-17 | — | — | EP | disclosed |
| US-20090075989-A1 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | BAYER SCHERING PHARMA AG (DE) | 2009-03-19 | — | — | US | disclosed |
| WO-2008077646-A1 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270381-A1 | Non-steroidal progesterone receptor modulators | PGR, PGRMC1, PGRMC2 | CYP2A6 134/4885BCL2 2800/4885PTGS2 48/4885 |
| US-20090075989-A1 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | NR5A1, CYP19A1, GPER1 | CYP2A6 118/4885BCL2 3423/4885PTGS2 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.